Johnson & Johnson will pay $2.2 billion to resolve civil
and criminal allegations involving the marketing of off-label, unapproved uses
for three prescription drugs, Justice Department officials announced Monday.
The cases, which date from the late 1990s through the early
2000s, involve alleged kickbacks to doctors and pharmacies to promote the
antipsychotic drugs Risperdal and Invega, and a heart drug, Natrecor. The
widely anticipated agreement was one of the largest health-care fraud
settlements in U.S. history.
Federal investigators accused a Johnson & Johnson
subsidiary of promoting Risperdal for controlling anxiety and aggression in
elderly dementia patients, as well as for treating behavioral problems in other
“vulnerable” populations, such as children and the mentally disabled. Read more.
No comments:
Post a Comment